Gilead says twice-yearly HIV prevention shot succeeds in second pivotal trial
Gilead announced that its twice-a-year HIV injection prevented all but two cases of HIV among 2,180 participants in a Phase 3 study as it prepares …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
